Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?

Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.

2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?

Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.